Physician profile
David Rios
NPI 1033965876
$1,425.01
in general payments reported to CMS, 2019-2025
19 companies · $999 in 2025
The $999 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $426 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $268.29 | 2024-2025 | |
| Madrigal Pharmaceuticals | $212.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $184.74 | 2025 | |
| Amgen INC. | $166.31 | 2025 | Evenity, Otezla, Repatha |
| Abiomed | $122.95 | 2024 | Impella |
| Dexcom, INC. | $64.05 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $62.96 | 2025 | |
| Lilly USA, LLC | $62.19 | 2025 | Jardiance |
| Novo Nordisk INC | $51.09 | 2024-2025 | Ozempic |
| Astrazeneca Pharmaceuticals Lp | $44.26 | 2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.23 | 2024 | Jardiance |
| Astellas Pharma US INC | $21.70 | 2025 | Veozah |
| Boston Scientific Corporation | $20.88 | 2025 | General - Pain Management |
| Pfizer INC. | $20.46 | 2025 | |
| Nalu Medical, INC. | $19.10 | 2025 | Nalu Neurostimulation System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $17.59 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $17.27 | 2024 | Fanapt |
| Exact Sciences Corporation | $13.85 | 2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.